<DOC>
	<DOCNO>NCT02402699</DOCNO>
	<brief_summary>This protocol conduct comply direct request Taiwan Food Drug Administration ( TFDA ) 60-month intensive pharmacovigilance protocol patient know hepatitis B ( HBV ) hepatitis C ( HCV ) infection , regardless control antiviral therapy Taiwan treat ipilimumab advance ( unresectable , recurrent metastatic ) Melanoma .</brief_summary>
	<brief_title>Ipilimumab 60-month Pharmacovigilance Protocol Advanced Melanoma Patients Who Are Hepatitis B and/or Hepatitis C Virus Positive Taiwan</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Age 18 year old date first dose Ipilimumab Patients receive least 1 dose Ipilimumab treatment unresectable , recurrent Metastatic Melanoma Taiwan Patients advance Melanoma HBV HCV initiate Ipilimumab discretion physician Patients receive Ipilimumab part clinical trial Patients receive Ipilimumab indication local approval ( ie , unresectable Metastatic Melanoma ) Patients infected HBV HCV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>HBV</keyword>
	<keyword>HBC</keyword>
</DOC>